Fecal microbiota transplantation (FMT) is a highly effective intervention for patients suf-2 fering from recurrent Clostridium difficile, a common hospital-acquired infection. FMT's 3 success as a therapy for C. difficile has inspired interest in performing clinical trials that 4 experiment with FMT as a therapy for other conditions like inflammatory bowel disease, 5 obesity, diabetes, and Parkinson's disease. Results from clinical trials that use FMT to 6 treat inflammatory bowel disease suggest that, for at least one condition beyond C. dif-7 ficile, most FMT donors produce stool that is not efficacious. The optimal strategies for 8 identifying and using efficacious donors have not been investigated. We therefore exam-9 ined the optimal Bayesian response-adaptive strategy for allocating patients to donors 10 and formulated a computationally-tractable myopic heuristic. This heuristic computes 11 the probability that a donor is efficacious by updating prior expectations about the ef-12 ficacy of FMT, the placebo rate, and the fraction of donors that produce efficacious 13 stool. In simulations designed to mimic a recent FMT clinical trial, for which traditional 14
power calculations predict ∼100% statistical power, we found that accounting for differ-15 ences in donor stool efficacy reduced the predicted statistical power to ∼9%. For these 16 simulations, using the heuristic Bayesian allocation strategy more than quadrupled the 17 statistical power to ∼39%. We use the results of similar simulations to make recommen-18 dations about the number of patients, number of donors, and choice of clinical endpoint 19 that clinical trials should use to optimize their ability to detect if FMT is effective for 20 treating a condition. 21 2 Introduction 22 Fecal microbiota transplant (FMT), the transfer of stool from a healthy person into an ill 23 person's gut, is a highly effective treatment for recurrent Clostridium difficile infections, 24 which kill 30,000 Americans a year. Despite FMT's efficacy and increasingly widespread 25 use, the biological mechanism by which FMT cures the infection is not fully understood 26 [1, 2, 3, 4, 5, 6, 7 ]. FMT's success in treating C. difficile has generated interest in 27 experiments that use FMT to treat other conditions related to the gut and the gut-28 associated microbiota [8, 9] . However, emerging evidence suggests using FMT for these 29 other diseases will be more challenging. Notably, in a recent study by Moayyedi et al. 30 [10] that used FMT to treat ulcerative colitis, patients appeared to respond to stool from 31 only one of the six stool donors. Stool from all other donors was no more efficacious than 32 placebo. These results suggest that the effectiveness of FMT can depend strongly on the 33 choice of stool donor. 34 Ideally, information collected before or during a clinical trial could be used to identify 35 which donors are efficacious. Predictions about a donor's efficacy could be repeatedly 36 updated depending on that donor's performance, the performance of other donors, and 37 prior expectations about donor efficacy and heterogeneity. There is, however, not enough 38 clinical information about this variability or biological information about the mechanism 39 by which FMT treats disease to create or validate a model for any particular indication. 40 We therefore present a general model of differences in donor stool efficacy that is not 41 specific to a clinical indication or biomarker. Using this model, we describe the optimal, 42 adaptive, Bayesian strategy for allocating donors and then formulate a computationally-43 tractable myopic Bayesian allocation heuristic. 44 Using simulations of clinical trials, we show that differences in donor efficacy and the 45 trial's strategy for allocating donors can have substantial impacts on the trial's statistical 46 power. We compare the performance of non-adaptive approaches for allocating patients 47 to donors against a variation of a previously-studied adaptive algorithm (a "play the 48 winner" strategy [11, 12, 13] ) and our own Bayesian heuristic. We find that, in many 49 cases, traditional non-adaptive allocation strategies are likely to falsely conclude that 50 FMT in inefficacious. Adaptive strategies, however, can substantially increase a trial's 51 ability to detect if FMT is efficacious. 52 3 Model of differences in donor stool efficacy 53 The results of the trial reported in Moayyedi et al. [10] raise the possibility that only 54 some donors produce stool that is efficacious for treating ulcerative colitis, a type of 55 inflammatory bowel disease. This possibility-that donors produce stool that is either 56 efficacious or not-is a special case of a more general model of donor-patient interaction. 57 In this general model, a patient in the treatment arm can respond to the treatment 58 under one of three scenarios: 59 1. the patient failed to respond to the FMT itself but did respond to the placebo 60 effect, 61 2. the patient responded to the FMT and would have responded to the placebo effect 62 if they had been given only a placebo, or 63 3. the patient responded to the FMT and would not have responded to a placebo. and the placebo effect-as independent. Specifically, we say that stool has some "active 66 ingredient" that, in the absence of a placebo effect, could cause a patient to respond.
67
In theory, stool from different donors could have different ingredient efficacies for 68 different patients. Assuming that there are discrete classes of patients and donors, we 69 write the ingredient efficacy of stool from a donor in class d for a patient in class t as 70 p (t,d) ingr . The probability p (t,d) eff that a patient in class t will respond to treatment (i.e., the 71 treatment efficacy) using a donor in class d depends on p (t,d) ingr and the probability p pl that 72 that patient will respond to the placebo effect:
The "matching" between patients and donors, if it exists, is not well understood and cannot yet be predicted. Furthermore, to minimize the patients' exposure to unknown pathogens, current FMT trials usually treat each patient with stool from only one donor.
Thus, each patient is selected randomly from the different patient classes, so the observed treatment efficacy p class t and f pl be the probability distribution function of the placebo rates so that:
Due to this limitation, we will model only the variables p
ingr and p pl with the under-74 standing that these variables are actually the mean values over distributions of patient 75 characteristics.
76
The study by Moayyedi et al. [10] suggests that the majority of donors produce stool 77 that has no efficacy beyond placebo, that is, that there is a class of donors for which 78 p (d) ingr = 0. In light of the paucity of the available data about donor qualities, we made a 79 further simplification to the model: we assert that a fraction f eff of donors have ingredient 80 efficacy p ingr > 0 and the remaining donors have p ingr = 0 (i.e., p eff = p pl ). This final 81 model is summarized in Figure 1 . Figure 1 : The model of differences in donor efficacy. In the model, donors are efficacious or not. Patients respond to FMT from an efficacious stool donor with probability p eff . An FMT from an inefficacious stool donor is considered identical to a placebo, i.e., patients respond with probability p pl . The fraction of donors in the general donor population that are efficacious is f eff .
Bayesian model formulation 83
Adaptive donor assignment strategies aim to use the information derived from the pa-84 tients' outcomes-and possibly some a priori beliefs about the values of the model 85 parameters-to make decisions about how to assign donors. The donor assignment prob-86 lem, then, is amenable to a Bayesian treatment, which will model the three parameters 87 described above as well as the "qualities" q ∈ {0, 1} D of the D donors, where q i = 0 88
indicates that donor i produces inefficacious (i.e., placebo-equivalent) stool and q i = 1 89
indicates that that donor produces efficacious stool.
90
As described in the Results, we found that the results of simulations using this model were mostly insensitive to the choice of prior distribution on the parameters (p pl , p ingr , f eff ), so in most cases we used a simple uniform prior on these values. In one set of simulations,
Clinical trial result
Parameter Point estimate A B 2 of 37 in placebo arm responded p pl 2/37 = 0.054 2 35 1 of 6 donors appeared efficacious f eff 1/6 = 0.17 1 5 7 of 18 patients allocated to the efficacious donor responded p eff 7/18 = 0.39 7 11 we articulated these priors using beta distributions:
where the hyperparameters A (·) and B (·) can be drawn from prior clinical trial results. 91 We chose to model the prior on p ingr via a beta distribution on p eff because p eff is directly 92 observable in terms of patient outcomes, while p ingr can only be back-computed from p eff 93 and p pl via equation (1) . The clinical trial results for Moayyedi et al.
[10] and their 94 translation into the model parameters and prior hyperparameters are shown in Table 1 . 95 We model the prior on the donor qualities q as a function of f eff , the fraction of donors 96
in the general population that are efficacious:
The data used to update the priors are the numbers of patients treated successfully 98 and unsuccessfully for each donor. The likelihood of the data X given these parameters 99
where Bin(s, n; p) is the binomial probability mass function with s successes among n 101 total trials with success probability p, s i is the number of patients successfully treated 102 with stool from donor i, and n i is the total number of patients treated with stool from 103 donor i.
104
Combining equations (6) and (7) shows that the posterior probability of the parame-105 ters q and π ≡ (p pl , p ingr , f eff ) is
where P (π) is the prior. The derivation of the posterior predictive probability of a patient 107 responding to treatment with stool from a given donor is in the Appendix.
108
We found no closed-form solution to the integrals required to compute the predictive 109 posterior probabilities, which we instead evaluated using numerical methods. Specifically, 110
we used Monte Carlo integration with Suave (SUbregion-Adaptive VEgas), an importance 111 sampling method combined with a globally adaptive subdivision strategy. Sampling for 112 this integral was performed with Sobol pseudo-random numbers. The integrator was 113 implemented in C++ using the Cuba package [14] . Wrappers for the integration routine 114 were implemented in Python 3 and simulations were then parallelized to run on multiple 115 cores to optimize computational run time [15] . is the optimal choice for the next donor? This question is similar to other "bandit" 119 problems [16] . Answering it requires evaluating the ramifications that a donor choice will 120 have for the next patient as well as for the trial as a whole.
121
Let a trial state be a trial with some set of observed patient outcomes. Given a donor 122 choice, each trial state has two child states: one in which the patient assigned to that 123 donor responded to treatment, one in which the patient did not respond. The optimal 124 donor choice is the one with maximum expected utility U , where the utility reflects the 125 outcome of the entire trial. The utility of a donor choice is
where p is the probability of a patient responding to treatment from that donor, S is the 127 child state with a success from that donor, and F is the child state with a new failed 128 patient.
129
FMT trials are often designed with a patient horizon (i.e., they will terminate after 130 N patients have been treated), and it is natural to associate utilities with the terminal 131 trial states. For example, it would be sensible to take the actions that are most likely to 132 lead to a trial with a significant p-value as measured by frequentist statistics, so every 133
terminal node with a significant p-value would have utility 1 and the others would have 134 utility 0.
135 Equation (9) shows that the optimal donor choice at a non-terminal trial state depends 136 only on the utility of its child nodes and each donor's probability of a successful treatment 137
given that trial state. with the maximum expected utility.
145
An algorithm for counting the number of unique trial states as a function of the 146 number N of patients treated, derived in the Appendix, shows that a moderate-size trial 147
with N = 30 has more than 10 million terminal trial states. Unfortunately, evaluating 148 the posterior predictive probability that a patient will respond to treatment from a donor 149 is computationally intensive, making this optimal approach infeasible. In light of the intractability of the optimal solution, we formulated a myopic heuristic 152 that, rather than optimizing the expected utility of the entire trial, simply assigns the 153 next patient to the donor that maximizes the probability that that patient will have a 154 successful outcome. At each step in the trial, the predictive posterior probability of a 155 successful patient outcome is computed for each donor, and the donor with the maximum 156 probability is used. (In the case of a tie, a donor is chosen at random.) Urn-based allocation Our urn-based allocation strategy is a variation on the "play-171 the-winner" strategies designed and studied as an ethical [17] and statistically-rigorous 172 way to decide how to allocate patients to a treatment arm when a trial includes more 173 than one treatment arm [18, 19, 20] . In this study, we used the generalized Pólya's urn 174
[21] with parameters w = 1, α = 3, β = 0, and without replacing the drawn ball.
175
Myopic Bayesian heuristic This is the strategy described in the previous section. 176
Except when noted, a uniform prior on the three parameters (p pl , p ingr , f eff ) was used. ters, 10,000 lists of 6 donors each were randomly generated. Donors were designated as 183 efficacious or not efficacious by random chance according to the frequency of efficacious 184 donors f eff . The same donor lists were used for simulations for each of the allocation 185 strategies.
186
In one set of simulations, the number of donors was varied among 1, 3, 5, 10, 15, and 187 30. For those simulations, lists of 30 donors were generated for each parameter set and 188 trial iteration. The lists were truncated for the simulations using less than 30 donors.
189
For each allocation strategy and donor list, a trial was simulated. rate consistent with self-reported, subjective outcomes [25, 26] ).
203
• The efficacy p eff of efficacious donors is either 0.4 (similar to the value in Table 1 ) 204 or 0.95 (efficacy of FMT to treat C. difficile infection).
205
• The frequency f eff of efficacious donors is either 0.15 (similar to the value in Table 1 ) 206 or 0.9 (reflective of the fact that almost any well-screened donor produces stool that 207
can successfully treat C. difficile infection).
208
• The number of patients in each of the treatment and control arms is 15, 30, or 60, 209 corresponding to a range of patient numbers typical for Phase I and small Phase II 210 clinical trials.
211
Of these combinations, the set of values most similar to the one in Table 1 is p pl = 0.05, 212 p eff = 0.4, f eff = 0.15, N patients = 30.
213
Computing statistical power After determining the outcome of all the patients in 214 the trial, the p-value of a one-sided Fisher's exact test (asserting that the response rate 215 in the treatment arm was greater) was calculated. The proportion of simulations that 216 produced p < 0.05 was the estimate of the statistical power for that allocation strategy 217 under those trial parameters. Confidence intervals were calculated using the method of 218
Clopper and Pearson [27] . Values are rounded to two or three significant digits. The purpose of adaptive donor allocation strategies is to identify and use efficacious 223 donors. We therefore expected that simulated trials that use adaptive strategies would 224 allocate more patients to efficacious donors (compared to simulated trials that used the 225 block or random donor allocation strategies).
226
For every parameter set simulated, the average fraction of patients allocated to effi-227 cacious donors was greater in the adaptive strategies (urn-based and myopic Bayesian) 228 than in the non-adaptive strategies (block and random; Table S1 ). The two non-adaptive 229 allocation strategies performed almost identically: for each parameter set, their results 230 differed by less than 1 percentage point. The two adaptive strategies performed similarly: 231
for half of the parameter sets, their results differed by less than 2 percentage points. In 232 the remaining parameter sets, their results varied by between 2 and 9 percentage points. 233
When efficacious donors are common (f eff = 0.9), the adaptive and non-adaptive 234 strategies performed similarly (Fig. 2) . In other cases, the performance of the two strate-235 gies differed substantially. For example, for the parameterization most similar to the one 236
in Table 1 , the random strategy allocated 15% of patients to efficacious donors while the 237 myopic Bayesian strategy allocated 41% of patients to efficacious donors. Because trials that used the adaptive donor allocation strategies allocated more patients 240 to efficacious donors than the trials that used the non-adaptive strategies, we expected 241 that trials using adaptive strategies would have greater statistical power.
242
The adaptive strategies consistently yielded higher statistical powers than the non-243 adaptive strategies (Table 2) Table 1 (top), the Bayesian myopic heuristic (red) allocated more patients to efficacious donors than random allocation (black) did. When efficacious donors are common (bottom; same parameters as top but with f eff = 0.9), the two strategies allocate similar numbers of patients to efficacious donors. For visual clarity, only trials in which there was at least one efficacious donor are shown.
larger. For example, for the parameterization most similar to the one in Table 1 , a trial 245 that uses random allocation is expected to have 9% power, while the myopic Bayesian 246 strategy can deliver 39% power. The gap in performance is smallest when selecting a 247 donor at random is likely to yield an efficacious donor: among the trials with f eff = 0.9, 248 the adaptive and non-adaptive statistical powers differed by less than 6 percentage points. 249
Low statistical powers when f eff is small are likely due to the fact that if all the avail-250 able donors are not efficacious, then no allocation strategy should make a trial achieve 251 significance. For example, if only 15% of donors are efficacious (f eff = 0.15) and there 252 are only 6 donors (the number used in these simulations), then we expect that 38% of 253 Table 2 : Adaptive strategies yield clinical trials with higher statistical power. "FMT power" is the power computed by simulating the results of trials that would occur if the frequency of efficacious donors if f eff . "Naive power" is the power computed in the situation in which all donors are efficacious (i.e., f eff = 1.0). All 95% confidence intervals on these values are within 1 percentage point of the reported value and are not shown.
trials will have no good donors (using the binomial distribution function). We therefore 254 separately analyzed the simulated trials in which no donors were efficacious and the sim-255 ulated trials in which at least one donor was efficacious (Table S2 ). When no donors are 256 efficacious, trials with adaptive or non-adaptive strategies have ∼0% power. Among trials 257 with at least one efficacious donor, the difference in statistical power between adaptive 258 and non-adaptive strategies is greater than the difference computed using the results of 259 all trials.
260
Conversely, the power computed in traditional calculations that do not account for 261 differences in donor efficacy (i.e., that assume that all donors are efficacious, or equiva-262 lently f eff = 1.0) is, in many cases, substantially higher than the power computed when 263 accounting for differences in donor efficacy ( Table 2 , column "Naive powers"). For ex-264 ample, for the parameter set most similar to the one in Table 1 , the naive calculation 265 predicts 94% power, but the calculation that accounts for differences in donor efficacy 266 predicts only 9% power for non-adaptive allocation strategies. The differences between 267 the powers computed by the naive method and our approach is largest when f eff is small. In these simulations, we varied the actual values of p pl and p eff but we always initialized 271 the adaptive algorithms the same ways. To determine the sensitivity of the adaptive 272 allocation algorithms' performance to their initialization, we simulated trials in which the 273 actual model parameters were fixed but the algorithms' initializations varied (Table S3 274 and Table S4 ). The myopic Bayesian algorithm's performance was mostly robust to the 275 parameterization of its prior distribution except when the prior was strong and inaccurate. 276
Accurate priors, weak priors, and uniform priors provide comparable performance. In 277 contrast, the urn algorithm delivered widely varying powers, from 15% to 40%, depending 278 on its parameterization. Increasing the number of available donors increases the probability that at least one of 282 them will be efficacious. We therefore determined, for each donor allocation strategy, 283 the number of available donors that optimized the trial's expected power. Simulations 284 showed that increasing the size of the donor "pool" almost always increased the power of 285 trials using the myopic Bayesian donor allocation but, depending on the parameter set, 286 could increase or decrease the power of trials using other allocation strategies (Table S5 ). 287 there is probably day-to-day and donor-to-donor variation in stool efficacy) and that all 306 patients receive one course of treatment (while, say, patients who do not respond to a 307 first treatment might be treated with stool from a different donor).
308
In our formulation of the model, we only considered optimizing the assignment of 309 patients to donors within the treatment arm, thus "protecting" the size of the placebo 310 arm. Future work could determine if there is a benefit to adaptively assigning patients 311 to the control or treatment arms based on estimations of the donors' quality. We also 312 assumed in our simulations that the outcome from all the previous patients treatments 313 are known before the donor for the next patient is selected. In reality, patients in an FMT 314 trial overlap. The urn-based method can still be used for overlapping patients [21] , but 315 the myopic Bayesian method would require some modification. The urn-based approach is 316 also randomized, which is desirable in clinical trials because it can reduce certain kinds of 317 bias [11] . Future work could adapt the myopic Bayesian heuristic, which is deterministic, 318 for adaptive randomization [28] and for delays between patient allocation and outcome 319 observation. Our results entail recommendations to clinicians. First, the powers we computed here are, 323 in many cases, well below the powers computed assuming that all donors are efficacious. 324 We therefore encourage researchers to consult our predictions about statistical power 325 when deciding on the size of their trials.
Second, a high placebo rate can substantially decrease the statistical power of an FMT 327 trial. We therefore encourage researchers to use the most stringent outcome measurement 328 possible (e.g., an endoscopic Mayo score for inflammatory bowel disease).
329
Third, adaptive donor allocation strategies consistently delivered higher statistical 330 power than traditional, non-adaptive approaches. We therefore recommend that re-331 searchers use such an adaptive strategy. The urn-based strategy has the advantages 332 that similar response-adaptive strategies may be familiar to clinicians, it is randomized, 333
and it is simple to implement. However, an urn-based strategy needs to be carefully 334 parameterized: a badly-parameterized urn-based strategy performs similarly to random 335 allocation. The adaptive Bayesian donor allocation algorithm performs well even when 336 using the "default" settings (a uniform prior) but is complex and deterministic. To fully 337 leverage this strategy, a clinician would need to consult the algorithm's output after ev-338 ery patient outcome and follow the algorithm's deterministic instructions, which might 339 introduce bias.
340
Fourth, adaptive algorithms benefit from having access to a "bank" of 10 or more 341 donors. Researchers hoping to achieve the full benefits of adaptive donor selection must 342 be prepared to change donors multiple times during the trial.
343
Finally, researchers reporting about FMT trials should include information about the 344 donors, notably how many donors were used and what proportion of patients allotted to 345 each donor responded to treatment. This information will help future researchers account 346 for differences in donor efficacy. The adaptive allocation strategies we described here have a narrow aim: to increase the 350 number of successful patient outcomes in a trial. In theory, an adaptive trial design is 351 capable of more. For example, if it were hypothesized that FMT succeeded or failed 352 because of the presence or absence of some particular microbial species in the donor's 353 stool, then an adaptive trial design could recommend donor choices that aim to identify 354 that critical species. 355 We did not pursue a hypothesis-centric approach because we believe it is premature. 356
Even the mechanism by which FMT treats C. difficile, the most well-studied case, remains 357
unclear. We expect that strong hypotheses about mechanism will come from retroactive 358 comparison of efficacious vs. inefficacious stool after clinical trials have definitively show 359 that FMT is effective for treating some disease. Our study aims to do exactly this. Until 360 then, we hope that our results about adaptive donor allocation help more patients benefit 361 from FMT and will help clinicians identify those conditions that FMT can treat. Let S i be the event that the next patient responds to treatment with stool from donor i. 450
The posterior predictive probability of S i is
The probability P (S i |π, q) is simply p eff is q i = 1 and p pl if q i = 0. Thus,
terms for other donors × P (π) prior dπ (11) The constant of proportionality is the same for all i: the quantity in equation (11) 452 should be divided by
Because the binomials in the equations (11) and (12) meaning that there are N N possible chains of donors and 2 N possible chains of outcomes, 461
However, many of those states are identical. In particular, we consider donors identical 463 unless they have a different number of successful or failed patient outcomes (e.g., AsAs is 464 identical to BsBs), and we consider trial states identical if the same results are achieved 465 in a different order (e.g., AsAf is identical to Af As). Thus, a unique trial set is a set 466 of ordered triples (d i , s i , f i ), where d i is the number of donors that each have had s i 467 successful and f i failed patient outcomes. N, M ) is defined by the recursion:
The number of trial states with N patients is w(N, N ).
469
Proof. We then justify each of the recursion rules. For N = 0 (i.e., no patients), there is 470 only one trial state: {(0, 0, 0)}. For N = 1 (i.e., one patient), there are two trial states: 471 and p pl = 0.05) was analyzed by separately estimating the power for the trials in which no donors were efficacious ("no efficacious donors") and in which at least one donor was efficacious ("some efficacious donors"). "All simulations" shows the same data as in Table 2 . For f eff = 0.9, none of the 10,000 simulations had a donor pool with no efficacious donors. All 95% confidence intervals are within 1 percentage point of the reported value and are not shown. Table S3 : Sensitivity of simulated clinical trial power to parameterization of the myopic Bayesian algorithm parameters. Starting from the parameter described in Table 1 , 10,000 trials using the myopic Bayesian donor allocation were simulated for each of six different parameterizations of the Bayesian algorithm. "Accurate" means that the prior is centered around the true value (i.e., that A A+B equals the true value); "inaccurate" means that the prior is centered at approximately double the true value (but that A + B has been held constant). "Strong" means that every hyperparameter is ten-fold greater; "weak" means that every hyperparameter is ten-fold smaller. "Uniform" means a uniform prior was used for all parameters. All 95% confidence intervals are within 1 percentage point of the reported value and are not shown. Table S4 : Sensitivity of simulated clinical trial power to urn parameterization. Using the parameter set described in Table 1 , 10,000 trials using the urn-based donor allocation were simulated for each of several combinations of the parameters for the urn model as described in [21] . We also vary whether drawn balls are replaced or not. All 95% confidence intervals are within 1 percentage point of the reported value and are not shown. Table S6 : The number of possible trial states for a given number of patients, assuming that the number of available donors is equal to the number of patients.
